Today, the U.S. Food and Drug Administration has approved oral contraceptives to reduce the risk of heart failure in adults with chronic kidney disease, including kidney failure, kidney failure, cardiovascular death, and disease progression.
Chronic kidney disease is an important public health issue, and there is an insatiable need for treatments that reduce the progression of the disease and improve outcomes. Today, the treatment of chronic kidney disease is a major step forward in helping people with kidney disease.
Aliza Thompson, MD. , Deputy Director, Cardiovascular Department, FDA Pharmaceutical Assessment and Research Center
Chronic kidney disease occurs when the kidneys are damaged and unable to filter blood regularly. As a result of this deficiency, patients may have problems with fluid, electrolytes (essential minerals for many body processes) and the accumulation of waste in the body. Chronic kidney disease can sometimes lead to kidney failure. Patients are also more likely to develop cardiovascular disease, including coronary heart disease.
In a multidisciplinary, double-blind study, the efficacy of Persia has been evaluated in patients with chronic kidney disease to improve renal function and reduce cardiovascular mortality. In this study, 4,304 patients were randomly assigned to receive Persian or placebo. The study included at least 50% reduction in renal function, renal improvement, or cardiovascular or renal failure compared to both groups. According to the results, 197 out of 2,152 patients received by Ferguson were at least one of the last completed out of a total of 312 out of 2,152 patients treated with placebo. The study also compared the two groups in the number of patients who were hospitalized for heart failure or those who died of cardiovascular disease. A total of 100 patients who received Farsigan were hospitalized or died compared to the 138 patients who received placebo.
Autoimmune or recessive polycystic ovary syndrome (characterized by multiple cysts) has not been studied and is not considered effective in the treatment of patients with kidney disease or chronic kidney disease.
Patients should not use Farsigan if they have a history of severe allergic reactions to the drug or are being treated by the Devil. Fournier gangrene serious and life-threatening cases have been reported in diabetics taking Farsigan. To reduce the risk of hypoglycemia, patients should consider low insulin secretion or insulin secretion if they are taking Fargigan. It can cause constipation, severe urinary tract infections, genital yeast infections, and metabolic acidosis or ketosis. Patients should evaluate their voice and kidney function before starting Farsiga.
In addition to diet and exercise, Fargiga was approved in 2014 to improve glycemic control in adults with type 2 diabetes.
Fargiga received nominations for Fast Track, Progressive Treatment and Pre-Assessment for the indicator approved today. It is designed to facilitate rapid track development and treatment of serious conditions and to accelerate the evaluation of medications for incomplete medical needs. Breakthrough Therapy is designed to speed up the development and evaluation of medications designed to treat a serious condition, and initial clinical data indicate that the drug may significantly improve treatment at the critical end point (s). Priority Assessment will focus on the overall focus and resources for drug applications and, if accepted, will significantly improve the effectiveness of medical safety, diagnosis or severe prevention compared to standard applications.
FDA approves Farscigan for AstraZeneca
U.S. Food and Drug Administration